Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis

详细信息    查看全文

• 作者：Maurizio Cutolo^a ; ^{mcutolo@unige.it} ; Steven G. Nadler^b ; ^{steven.nadler@bms.com}
• 关键词：Rheumatoid arthritis ; CTLA-4-Ig ; Macrophages ; Endothelial cells ; Osteoclasts ; Co-stimulatory molecules
• 刊名：Autoimmunity Reviews
• 出版年：2013
• 出版时间：May, 2013
• 年：2013
• 卷：12
• 期：7
• 页码：758-767
• 全文大小：704 K

文摘

Rheumatoid arthritis (RA) is a multifactorial and polygenic immune-mediated disease, the pathogenesis of which involves different cell types. T and B lymphocytes, macrophages, endothelial cells, fibroblasts and osteoclasts have all been implicated in mediating the production of autoantibodies, proinflammatory cytokines and ultimately bone erosions. Cytotoxic T lymphocyte-associated antigen 4 immunoglobulin fusion protein (CTLA-4-Ig, abatacept) is a unique biologic agent targeting the co-stimulatory molecules CD80/CD86, and is indicated for the treatment of moderate-to-severe RA in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs, including methotrexate or anti-tumor necrosis factor agents. There is a growing body of evidence that, through selective modulation of the CD80/CD86 co-stimulatory molecules expressed by a variety of activated cell types, CTLA-4-Ig may inhibit the pathogenic RA process at several levels, both directly and indirectly. Here, we provide an overview of recent mechanistic studies of the action of CTLA-4-Ig on different cell types involved in mediating inflammation and joint damage in RA.